Generation Bio Co - Asset Resilience Ratio
Generation Bio Co (GBIO) has an Asset Resilience Ratio of 55.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Generation Bio Co's Asset Resilience Ratio has changed over time. Check how strategically is Generation Bio Co's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Generation Bio Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see GBIO market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $67.68 Million | 55.52% |
| Total Liquid Assets | $67.68 Million | 55.52% |
Asset Resilience Insights
- Very High Liquidity: Generation Bio Co maintains exceptional liquid asset reserves at 55.52% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Generation Bio Co Industry Peers by Asset Resilience Ratio
Compare Generation Bio Co's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Generation Bio Co (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Generation Bio Co.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 47.11% | $108.92 Million | $231.20 Million | -5.70pp |
| 2023-12-31 | 52.81% | $197.92 Million | $374.76 Million | +3.40pp |
| 2022-12-31 | 49.41% | $185.92 Million | $376.26 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $476.77 Million | -- |
| 2020-12-31 | 67.80% | $199.44 Million | $294.15 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $42.14 Million | -- |
| 2018-12-31 | 80.90% | $67.56 Million | $83.52 Million | -- |
About Generation Bio Co
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise me… Read more